Evaluation of clinical efficacy of Gefapixant Citrate

The efficacy evaluation of Gefapixant Citrate (Gefapixant Citrate) is mainly based on its objective and subjective indicators of improvement in chronic cough frequency and patient quality of life. In a randomized controlled study conducted overseas, the drug was shown for the first time to significantly reduce the number of coughs within 24 hours and improve patients' daily life problems. Chronic cough is not only the problem of frequent coughing itself, but is also often accompanied by decreased sleep quality, social restrictions and psychological stress. Therefore, the efficacy evaluation takes into account both objective counts and the improvement of the patient's subjective feelings.

Clinical data showed that patients treated with Gemfapixin experienced a significantly greater decrease in cough times per hour than those in the placebo group. This sustained improvement can be observed both during the day and at night, and is of significant significance for relieving the trouble caused by coughing during daily activities, improving sleep patterns, and improving quality of life. Patients report that the reduction in coughing not only reduces physical fatigue, but also reduces social anxiety and work interference. Especially for people who have long suffered from chronic cough, Gemfapixen provides actual and perceptible symptom improvement.

It is worth noting that the causes of chronic cough are complex, and P2X3 receptor inhibition alone cannot fully cover all patients. Overseas experts emphasized that the efficacy of Gemfapixin is most obvious in the "refractory cough" population, that is, patients who have tried a variety of central or peripheral interventions in the past but still have poor results. This also reflects the importance of individualized treatment. Before using Gemfapixin, doctors usually evaluate the patient's previous treatment history, control of triggers, and comorbid disease conditions to determine the value of the medication.

Taken together, Gemfapixin brings new options for the treatment of chronic cough through new neural pathway intervention. Its efficacy is sustainable and significant in appropriate patients, but it still needs to be combined with life intervention and potential trigger management to achieve long-term stable control.

Reference materials:https://go.drugbank.com/drugs/DB15097